Table 1 Correlation of selected clinical parameters and MCM3 expression with clinical outcome in the 3 cohorts of breast cancer patients where MCM3 expression was measured by immunohistochemistry.

From: MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit

 

Cohort 1

Cohort 2

Cohort 4

RFS

OS

RFS

OS

RFS

BCSS

Clinical parameter

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

MCM3

0.0026

2.7 (1.4–5.3)

0.007

2.5 (1.3–4.6)

0.01

2.0 (1.2–3.3)

0.16

1.4 (0.89–1.89)

0.033

2.5 (1.1–5.7)

0.044

2.9 (1.0–8.1)

Lymph node

0.002

2.4 (1.4–4.2)

0.002

2.5 (1.4–4.6)

0.0001

2.6 (1.7–4.0)

0.0001

2.1 (1.5–3.0)

NA

–

NA

–

Tumor size

0.4

0.9 (0.6–1.4)

0.9

0.9 (0.6–1.5)

0.005

1.7 (1.2–2.4)

0.002

1.6 (1.2–2.1)

0.7

1.2 (0.5–2.6)

0.065

2.4 (0.9–5.9)

Age

0.9

0.9 (0.9–1.0)

0.7

1.0 (0.9–1.1)

0.87

1.0 (0.96–1.03)

0.02

1.2 (1.0–1.05)

0.3

0.7 (0.3–1.4)

0.7

0.8 (0.3–2.1)

Tumor grade

0.012

3.4 (1.3–8.9)

0.03

2.6 (1.1–6.6)

0.6

1.1 (0.85–1.3)

0.8

1.02 (0.85–1.2)

0.1

1.6 (0.8–3.3)

0.3

1.6 (0.7–3.8)

  1. Variables were analyzed as follows: MCM3 (+ vs. −), tumor size (<20 mm vs. >20 mm), tumor grade (1 vs. 2 and 3), nodal status (+ vs. −), age (< or = 59 vs. > 59). 95% CI (95% confidence interval). Bold data represent significant values. RFS relapse-free survival, OS Overall survival, BCSS breast cancer-specific survival.
Back to article page